Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK

British Journal of Cardiology

Volumn 13, Issue 3, 2006, Pages 196-202

  Davies, Andrew ^a   Hutton, John ^a   O'Donnell, John ^b   Kingslake, Sarah ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Cost effectiveness; Genetics; Hypercholesterolaemia; Primary prevention; Statins; Uk

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GENERIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SMOKING; STATISTICAL MODEL; SURVIVAL TIME; TREATMENT OUTCOME; UNCERTAINTY; UNITED KINGDOM;

EID: 33745438950     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Lee TH, Cleeman JI, Grundy SM et al. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. JAMA 2000;283:94-8.
2. Shepherd J, Cobbe SM, Ford I et al. for WOSCOPS. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-06.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
5. LaRosa JC, Grundy SM, Waters DD et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
6. Wilson K, Marriott J, Fuller S, Lacey L, Gillen D. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels. Pharmacoeconomics 2003;21 (suppl 1):1-11.
7. Palmer SJ, Brady AJ, Ratcliffe AE. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. Int J Clin Pract 2003;57:792-800.
8. Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60.
9. Wilson PWF, d'Agostino RB, Levy D et al. Predictions of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
10. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991;121(1 Pt 2):293-8.
11. D'Agostino RB, Russell MW, Huse DM et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139(2 Pt 1):272-81.
12. Grieve R, Hutton J, Green C. Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field. Health Policy 2003;64(3):311-24.
13. Johnston K, Gray A, Moher M, Yudkin P, Wright L, Mant D. Reporting the cost-effectiveness of interventions with non-significant effect differences: example from a trial of secondary prevention of coronary heart disease. Int J Technol Assess Health Care 2003;19:476-89.
14. Ballantyne CM, McKenney J, Trippe BS. Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemia. Am J Cardiol 2000;86:759-63.
15. Brindle P, Emberson J, Lampe F et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 2003;327:1267.
16. The Government Actuary's Department. Expectation of Life. http://www.gad.gov.uk/
17. Rosengren A, Wilhelmsen L, Hagman M, Wedel H. Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16-year follow-up of the Primary Prevention Study, Goteborg, Sweden. J Int Med 1998;244:495-505.
18. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 2004;35:731-5.
19. Fried LP, Kronmal RA, Newman AB et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA 1998;279:585-92.
20. Jones L, Griffin S, Palmer S et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of clopidogrel and modified release dipyridamole in the secondary prevention of occlusive vascular events. http://www.nice.org.uk/pdf/HTAreportVasculardisease.pdf
21. Lacey EA, Walters SJ. Continuing inequality: gender and social class influences on self perceived health after a heart attack. J Epidemiol Community Health 2003;57:622-7.
22. Sandercock P, Berge E, Dennis M. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischernic stroke assessed by a model based on UK NHS costs. Stroke 2004;35:1490-7.
23. Bosch JL, Hunink MG. Comparison of the Health Utilities Index Mark 3 (HU13) and the EuroQol EQ-5D in patients treated for intermittent claudication. Qual Life Res 2000;9:591-601.
24. Drug Tariff. London: The Stationery Office, November 2005.
25. Palmer S, Sculpher M, Philips Z et al. A cost-effectiveness model comparing alternative management strategies for the use of glycoprotein IIB/IIIA antagonists in non ST elevation acute coronary syndrome. http://www.nice.org.uk/Docref.asp?d=36361 (accessed Feb 2004).
26. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003;21(suppl 1):43-50.
27. Mant J, Wade D, Winner S. 2003. Stroke. http://hcna.radcliffe-oxford.com/stroke.htm
28. Stewart S, Blue L, Walker A, Morrison C, McMurray JJ. An economic analysis of specialist heart failure nurse management in the UK; can we afford not to implement it? Eur Heart J 2002;23:1369-78.
29. Department of Health. National schedule of reference costs 2003. London: Department of Health, 2003. ]
30. National Institute for Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2004.
31. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Medical Decision Making 2002;22:290-308.
32. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Medical Decision Making 2003;23:341-50.
33. Haq IU, Ramsay LE, Jackson PR et al. Is the Framingham risk function valid for northern European populations? Heart 1999;81:40-6.
34. Ramachandran S, French JM, Vanderpump MP, Croft P, Neary RH. Should treatment recommendations for lipid lowering drugs be based on absolute coronary risk or risk reduction? BMJ 2000;320:677-9.
35. Canadian Coordinating Office for Health Technology Assessment. A clinical and economic review of HMG-CoA reductase inhibitors in coronary heart disease. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1998.